CSIMarket
 



Abbott Laboratories  (ABT)
Other Ticker:  
 
 


Abbott Laboratories Segments

 
Established Pharmaceutical Products
   18.66 % of total Revenue
Pediatric Nutritionals
   22.97 % of total Revenue
Adult Nutritionals
   24.83 % of total Revenue
Nutritionals
   34.74 % of total Revenue
Endovascular
   7.53 % of total Revenue
Vascular
   13.05 % of total Revenue
Diagnostics
   22.45 % of total Revenue
Other
   11.11 % of total Revenue
 

Business Segments (Sep. 30, 2015)
Revenues
(in millions $)
III. Quarter
%
(of total Revenues)
(Sep. 30, 2015)
Income
(in millions $)
III. Quarter
%
(Profit Margin)
Established Pharmaceutical Products
961.00 18.66 % 177.00 18.42 %
Pediatric Nutritionals
1,183.00 22.97 % 0.00 -
Adult Nutritionals
1,279.00 24.83 % 0.00 -
Nutritionals
1,789.00 34.74 % 459.00 25.66 %
Endovascular
388.00 7.53 % 0.00 -
Vascular
672.00 13.05 % 239.00 35.57 %
Diagnostics
1,156.00 22.45 % 307.00 26.56 %
Other
572.00 11.11 % 0.00 -
Total
5,150.00 100 % 1,182.00 22.95 %

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (Sep. 30, 2015)
Y/Y Revenue
%
III. Quarter
Q/Q Revenue
%
(Sep. 30, 2015)
Y/Y Income
%
III. Quarter
Q/Q Income
%
Established Pharmaceutical Products
24.64 % -1.64 % 10.63 % 2.91 %
Pediatric Nutritionals
3.95 % 50.51 % - -
Adult Nutritionals
-1.92 % 54.47 % - -
Nutritionals
0.11 % 4.19 % 24.39 % 17.99 %
Endovascular
-0.77 % 50.97 % - -
Vascular
-7.95 % -6.93 % -14.64 % -14.64 %
Diagnostics
-2.03 % -1.78 % -0.97 % 0.99 %
Other
-10.06 % -0.87 % - -
Total
0.9 % -0.39 % 5.63 % 3.23 %

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Abbott Laboratories's Established Pharmaceutical Products, Pediatric Nutritionals, Adult Nutritionals, Nutritionals, Endovascular, Vascular, Diagnostics, Other, Total segment. Select each division with the arrow.

  Abbott Laboratories's

Business Segments Description



Pharmaceutical Products

The Pharmaceutical Products segment’s products include a broad line of adult and pediatric pharmaceuticals manufactured, marketed and sold worldwide, which are sold primarily on the prescription, or recommendation, of physicians. In 2006, Abbott announced a collaboration with AstraZeneca to co-develop and market a fixed-dose combination lipid management therapy of Crestor® (rosuvastatin/AstraZeneca) with either Tricor® (Abbott’s fenofibrate) or Abbott’s next generation fenofibrate, ABT 335.

Diagnostic Products

The Diagnostic Products segment’s products include diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physicians’ offices, alternate-care testing sites, plasma protein therapeutic companies, and consumers.

The principal products included in the Diagnostic Products segment are:

· immunoassay systems, including ARCHITECT®, AxSYM®, IMx®, Abbott Quantum™, Commander®, Abbott PRISM®, TDx®, and TDxFlx®;

· chemistry systems such as ARCHITECT® c8000® and Aeroset®;

· assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases such as hepatitis and HIV;

· the Vysis® product line of genomic-based tests, including the PathVysion® HER-2 DNA probe kit and the UroVysion™ bladder cancer recurrence kit;

· a full line of hematology systems and reagents known as the Cell-Dyn® series;

· the product line of FreeStyle® blood glucose monitoring meters, test strips, data management software and accessories for people with diabetes, including FreeStyle®Freedom™, FreeStyle®, FreeStyle Flash® (sold in certain international markets as FreeStyle® Mini), FreeStyle Papillon™, and FreeStyle Tracker®, and other blood glucose monitoring meters, test strips, data management software and accessories, including Precision Xtra™, MediSense Optium™, Precision PCx®, Precision Q.I.D.®, MediSense II™, TrueMeasure® strips, Precision Link® Direct, and Precision® Sure-Dose® insulin syringes; and

· the i-STAT® point-of-care diagnostic systems and tests for blood analysis, including the i-STAT® system.

In addition, under its strategic alliance with Celera Diagnostics, a business of the Celera Genomics Group of Applera Corporation, the Diagnostic Products segment develops, manufactures and markets a broad range of in vitro molecular diagnostic products for disease detection, disease progression monitoring, and therapy selection. Through a sales and marketing agreement with Enfer Scientific Ltd., the Diagnostic Products segment also distributes diagnostic tests in Europe and Japan that are used to detect bovine spongiform encephalopathy (BSE) in cattle.

Vascular Products

The Vascular Products segment’s products include a broad line of coronary, endovascular and vessel closure devices used in the treatment of vascular disease. In April 2006, Abbott acquired Guidant Corporation’s vascular intervention and endovascular solutions businesses.

The principal products included in the Vascular Products segment are:

· Multi-Link Vision®, and Multi-Link Mini Vision®, coronary metallic stents;

· Xience V®, a next-generation drug-eluting coronary stent system developed on the Multi-Link Vision platform;

· BMW® and Asahi coronary guidewires;

· StarClose®, a vessel closure device;

· Acculink®/Accunet® and Xact®/Emboshield®, carotid stent systems; and

· Voyager® balloon dilation products.

The Vascular Products segment markets its products worldwide. These products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.

The Vascular Products segment’s products are subject to competition in technological innovation, price, convenience of use, service, product performance, long-term supply contracts, and product potential for overall cost-effectiveness and productivity gains. Some products in this segment can be subject to rapid product obsolescence. Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products

   

Sales by Geography Competition By Business Segments Company Profile
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

INPX's Profile

Stock Price

INPX's Financials

Business Description

Fundamentals

Charts & Quotes

INPX's News

Suppliers

INPX's Competitors

Customers & Markets

Economic Indicators

INPX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071